Physician profile
Robert L Bailey
NPI 1902032352
$11,635.41
in general payments reported to CMS, 2019-2025
17 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $114 · 2021: $1,247 · 2022: $3,702 · 2023: $3,790 · 2024: $1,170 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414 · Travel and Lodging: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,414.45 |
| Travel and Lodging | $1,898.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,865.29 | 2021-2025 | Mazor X System, Vanta Adaptivestim, Osteocool Rf Ablation System |
| Globus Medical, INC. | $3,572.56 | 2022-2025 | Excelsiusgps Robotic Navigation System, Excelsius Gps |
| Stryker Corporation | $1,540.16 | 2019-2024 | Serrato, Cascadia Interbody System, N/A |
| Abbott Laboratories | $900.61 | 2023-2025 | Eterna, Proclaim |
| Nuvasive, INC. | $267.43 | 2019-2023 | Alif, Vuepoint, Reline |
| Kuros Biosciences USA, INC | $208.61 | 2024-2025 | Magnetos |
| Carlsmed, INC. | $181.94 | 2025 | Aprevo |
| Cerapedics INC. | $181.43 | 2024 | I-Factor Peptide Enhanced Bone Graft |
| Boston Scientific Corporation | $154.33 | 2025 | Intracept |
| Si-Bone, INC. | $143.48 | 2025 | |
| Amgen INC. | $140.36 | 2024 | Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $126.02 | 2023-2024 | Entyvio |
| Nevro Corp. | $112.95 | 2019 | |
| Depuy Synthes Sales INC. | $89.21 | 2024 | Teligen |
| Smith+Nephew, INC. | $59.23 | 2025 | Pico 7, Pico 14 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $47.84 | 2025 | Rezdiffra |
| Musculoskeletal Transplant Foundation INC. | $43.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.